DRCRN (Diabetic Retinopathy Clinical Research Network) Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy – Protocol J

Who is the sponsor?
National Eye Institute (NEI)

Who are the patients?
Individuals with macular edema (swelling of the central part of the retina) associated with diabetic retinopathy. The participating doctor will evaluate you to determine your eligibility into the study in accordance with the Study Eligibility and Exclusion Criteria.

How long is the trial?
Participants will be monitored for one year.

When did participation start at our site?
June 2007

What is the enrollment goal for the sponsor?
381 patients

Is the enrollment still open?

What is this study investigating?
This is a prospective, multi-center, randomized study with the following objective: Evaluate whether intravitreal injection of an anti-VEGF drug or an intravitreal injection of a corticosteroid can reduce the risk of visual acuity impairment that can occur following PRP and increase the chances of at least short-term visual acuity improvement in eyes with evidence of center-involved macular edema that are undergoing PRP for PDR.

How is the treatment administered?
Ranibizumab (Lucentis) and triamcinolone acetonide are given as an injection into the eye. In focal photocoagulation and panretinal photocoagulation a powerful beam of light (laser) is focused onto the retina using a specialized set of ophthalmic equipment and lenses.